Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04530487
Other study ID # 2020-0496
Secondary ID NCI-2020-0587920
Status Recruiting
Phase Phase 2
First received
Last updated
Start date August 19, 2020
Est. completion date May 9, 2025

Study information

Verified date April 2024
Source M.D. Anderson Cancer Center
Contact Jeremy S Connors, MD
Phone (713) 792-6624
Email jsconnors@mdanderson.org
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This phase II trial investigates side effects and how well donor stem cell transplant after chemotherapy works in treating pediatric and adolescent-young adults with high-risk solid tumor that has come back (recurrent) or does not respond to treatment (refractory). Chemotherapy drugs, such as fludarabine, thiotepa, etoposide, melphalan, and rabbit anti-thymocyte globulin work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving chemotherapy before a donor stem cell transplant helps kill cancer cells in the body and helps make room in the patient's bone marrow for new blood-forming cells (stem cells) to grow. When the healthy stem cells from a donor are infused into a patient, they may help the patient's bone marrow make more healthy cells and platelets and may help destroy any remaining cancer cells.


Description:

PRIMARY OBJECTIVE: I. To assess tolerability of allogeneic hematopoietic stem cell transplantation (HCT) for patients with chemo-responsive recurrent/refractory solid tumors as defined by transplant-related mortality (TRM) at day 30 and the rate of grade III or higher organ toxicity (Bearman Regimen-Related Toxicities Scale) attributable to conditioning occurring within 30 days. SECONDARY OBJECTIVES: I. Assess median time to platelet and neutrophil engraftment. II. Assess incidence of acute graft-versus-host disease (aGVHD) by day 100. III. Assess incidence of chronic GVHD (cGVHD) at day 100 and one year. IV. Assess rate of grade II organ toxicity through day 100. V. Assess rate of graft failure (primary and secondary) through day 100. VI. Assess rate of infectious complications through day 100. VII. Assess progression free survival (PFS) at day 100,180 and 365. VIII. Assess cumulative incidence of relapse, overall survival (OS) at 100 days and 1 year. OUTLINE: CONDITIONING REGIMEN: Patients receive thiotepa intravenously (IV) over 2-4 hours and etoposide IV over 60 minutes on days -8 to -6, melphalan IV over 20 minutes on days -5 and -4, and fludarabine phosphate IV over 1 hour on days -5 to -3 in the absence of disease progression or unacceptable toxicity. Patients receiving umbilical cord transplant also receive rabbit anti-thymocyte globulin IV on days -4 and -3. TRANSPLANT: Patients undergo HSCT on day 0. GVHD PROPHYLAXIS: Beginning day -2, patients receive tacrolimus or cyclosporine IV continuously until able to receive orally (PO). Patients continue tacrolimus or cyclosporine PO to day 60 and tapered to day 100. Patients also receive mycophenolate mofetil PO or IV every 8 hours until day 40 and tapered to day 90. After completion of HSCT, patients are followed up for up to 1 year.


Recruitment information / eligibility

Status Recruiting
Enrollment 40
Est. completion date May 9, 2025
Est. primary completion date May 9, 2025
Accepts healthy volunteers No
Gender All
Age group N/A to 25 Years
Eligibility Inclusion Criteria: - Pathological criteria, including malignant recurrent/refractory solid tumors. This would include: - Ewing's/peripheral primitive neuroectodermal tumor (PNET) - Malignant peripheral nerve sheath tumor, neurofibrosarcoma - Rhabdomyosarcoma - Neuroblastoma (patients who are ineligible for tandem autologous transplant or who are at least 3 months post autologous HCT) - Desmoplastic small round cell tumor (DSRCT)- both new diagnoses as well as recurrent/refractory disease - Patients must have chemo-responsive disease, defined as; 30% or greater decrease in the tumor target lesions when compared to its pre-treatment evaluation. Patients with complete response will be eligible to participate - Available suitable HCT donor - Creatinine clearance or glomerular filtration rate (GFR) >= 50 ml/min/1.73m^2, and not requiring dialysis - Diffusing capacity of lung for carbon monoxide (DLCO) (corrected for hemoglobin) >= 50% predicted. If unable to perform pulmonary function tests, then oxygen (O2) saturation >= 92% in room air - Bilirubin =< 3 x upper limit of normal (ULN) and alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 5 x for age (with the exception of isolated hyperbilirubinemia due to Gilbert's syndrome) - DONOR: Matched related donor bone marrow (10 of 10 HLA alleles [HLA-A, B, C, DR, and DQ]. Matched related donor peripheral blood stem cell (PBSC) is allowed only if collection of bone marrow (BM) is not available or refused by parents/donor - DONOR: Matched allogeneic umbilical cord blood (UCB): related - High-resolution matching at A,B, DRB1 (minimum 4/6) - KIR major histocompatibility complex (MHC) class 1 preferential mismatch (minimum 4/6) - DONOR: Matched allogeneic umbilical cord blood: unrelated - High-resolution matching at A,B, DRB1 (minimum 4/6) •*KIR MHC class 1 preferential mismatch (minimum 4/6) Exclusion Criteria: - Lack of histocompatible suitable related donor/ graft source - End-organ failure that precludes the ability to tolerate the transplant procedure, including conditioning regimen - Renal failure requiring dialysis - Congenital heart disease resulting in congestive heart failure - Ventilatory failure: requires invasive mechanical ventilation - Human immunodeficiency virus (HIV) infection - Uncontrolled bacterial, viral, or fungal infections (currently taking medication yet clinical symptoms progress); stable, controlled disease with treatment is not an exclusion criteria - A female of reproductive potential who is pregnant, planning to become pregnant during the study, or is nursing a child - Any patient who does not fulfill the inclusion criteria listed above

Study Design


Related Conditions & MeSH terms

  • Desmoplastic Small Round Cell Tumor
  • Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor
  • Neoplasms
  • Nerve Sheath Neoplasms
  • Neuroblastoma
  • Neuroectodermal Tumors
  • Neuroectodermal Tumors, Primitive
  • Neuroectodermal Tumors, Primitive, Peripheral
  • Recurrence
  • Recurrent Desmoplastic Small Round Cell Tumor
  • Recurrent Malignant Peripheral Nerve Sheath Tumor
  • Recurrent Malignant Solid Neoplasm
  • Recurrent Neuroblastoma
  • Recurrent Rhabdomyosarcoma
  • Refractory Desmoplastic Small Round Cell Tumor
  • Refractory Malignant Peripheral Nerve Sheath Tumor
  • Refractory Malignant Solid Neoplasm
  • Refractory Neuroblastoma
  • Refractory Rhabdomyosarcoma
  • Rhabdomyosarcoma
  • Sarcoma, Ewing

Intervention

Procedure:
Allogeneic Hematopoietic Stem Cell Transplantation
Undergo HSCT
Drug:
Cyclosporine
Given IV and PO
Etoposide
Given IV
Fludarabine Phosphate
Given IV
Biological:
Lapine T-Lymphocyte Immune Globulin
Given IV
Drug:
Melphalan
Given IV
Mycophenolate Mofetil
Given IV or PO
Tacrolimus
Given IV and PO
Thiotepa
Given IV

Locations

Country Name City State
United States M D Anderson Cancer Center Houston Texas

Sponsors (1)

Lead Sponsor Collaborator
M.D. Anderson Cancer Center

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Transplant-related mortality (TRM) The proportion of patients with 30-day TRM will be reported together with the corresponding 95% Bayesian credible interval. At 30 days
Primary Rate of grade III or higher organ toxicity attributable to conditioning Assessed using the Bearman Regimen-Related Toxicities Scale. The proportion of patients with 30-day grade III or higher organ toxicity will be reported together with the corresponding 95% Bayesian credible interval. Up to 30 days
Secondary Time to platelet and neutrophil engraftment Will be calculated and illustrated from the time of transplant by the method of Kaplan and Meier. Up to 1 year post transplant
Secondary Incidence of acute graft versus host disease (aGVHD) The 100-day rates of acute with the competing risk of relapse will be estimated using the method of Gooley. At 100 days post transplant
Secondary Incidence of chronic GVHD The 100-day rates of chronic GVHD with the competing risk of relapse will be estimated using the method of Gooley At 100 days post transplant
Secondary Incidence of chronic GVHD The 1 year rates of chronic GVHD with the competing risk of relapse will be estimated using the method of Gooley. At 1 year post transplant
Secondary Rate of grade II organ toxicity The 100-day rates of grade II organ toxicity will be reported as counts with percentages. Up to 100 days post transplant
Secondary Rate of graft failure (primary and secondary) The 100-day rates of primary and secondary graft failure will be reported as counts with percentages. Up to 100 days post transplant
Secondary Rate of infectious complications The 100-day rates of infectious complications will be reported as counts with percentages. Up to 100 days post transplant
Secondary Progression-free survival (PFS) Will be assessed using the method of Kaplan and Meier. At 180 days post transplant
Secondary PFS Will be calculated and illustrated from the time of transplant by the method of Kaplan and Meier. At 100 days post transplant
Secondary PFS Will be calculated and illustrated from the time of transplant by the method of Kaplan and Meier. At 1 year post transplant
Secondary Incidence of relapse Will be calculated and illustrated from the time of transplant by the method of Kaplan and Meier. At 100 days post transplant
Secondary Incidence of relapse Will be calculated and illustrated from the time of transplant by the method of Kaplan and Meier. At 1 year post transplant
Secondary Overall survival (OS) Will be calculated and illustrated from the time of transplant by the method of Kaplan and Meier. At 100 days post transplant
Secondary OS Will be calculated and illustrated from the time of transplant by the method of Kaplan and Meier. At 1 year post transplant
See also
  Status Clinical Trial Phase
Completed NCT00939770 - Crizotinib in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma Phase 1/Phase 2
Withdrawn NCT03925428 - Testing a New Anti-cancer Drug Combination, Entinostat and GSK525762C, for Advanced and Refractory Solid Tumors and Lymphomas Phase 1
Active, not recruiting NCT03233204 - Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial) Phase 2
Active, not recruiting NCT04294628 - Testing the Biological Effects of DS-8201a on Patients With Advanced Cancer Phase 1
Active, not recruiting NCT03065387 - Neratinib and Everolimus, Palbociclib, or Trametinib in Treating Participants With Refractory and Advanced or Metastatic Solid Tumors With EGFR Mutation/Amplification, HER2 Mutation/Amplification, or HER3/4 Mutation or KRAS Mutation Phase 1
Active, not recruiting NCT03213691 - Selumetinib Sulfate in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial) Phase 2
Active, not recruiting NCT02323880 - Selinexor in Treating Younger Patients With Recurrent or Refractory Solid Tumors or High-Grade Gliomas Phase 1
Recruiting NCT05455606 - Does the Use of a Genomic Tumor Board Increase the Number of Patients Who Receive Genome-Informed Treatment N/A
Recruiting NCT04981691 - Anti-mesothelin CAR-T Cells With Advanced Refractory Solid Tumors Phase 1
Recruiting NCT04851119 - Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors Phase 1/Phase 2
Active, not recruiting NCT03220035 - Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial) Phase 2
Active, not recruiting NCT03213678 - Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial) Phase 2
Recruiting NCT04119024 - Gene Modified Immune Cells (IL13Ralpha2 CAR T Cells) After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors Phase 1
Recruiting NCT05286801 - Tiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors Phase 1/Phase 2
Recruiting NCT05053971 - Testing A New Anti-cancer Drug Combination, Entinostat and ZEN003694, for Advanced and Refractory Solid Tumors and Lymphomas Phase 1/Phase 2
Active, not recruiting NCT03698994 - Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial) Phase 2
Completed NCT01709435 - Cabozantinib S-Malate in Treating Younger Patients With Recurrent or Refractory Solid Tumors Phase 1
Active, not recruiting NCT03213665 - Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial) Phase 2
Not yet recruiting NCT03205644 - VX15/2503 in Treating Younger Patients With Recurrent, Relapsed, or Refractory Solid Tumors Phase 1/Phase 2
Recruiting NCT06320405 - Axatilimab in Combination With Retifanlimab and Paclitaxel for the Treatment of Patients With Advanced or Metastatic Solid Tumors Phase 1/Phase 2

External Links